What administration frequency is recommended for Abaloparatide (Tymlos)?

• A. Daily
• B. Weekly
• C. Monthly
• D. Every other week

Answer: (A)

Abaloparatide, marketed under the brand name Tymlos, is a synthetic analog of parathyroid hormone used for the treatment of osteoporosis in postmenopausal women at high risk for fracture. The recommended administration frequency for Abaloparatide is daily, typically delivered via subcutaneous injection.

Administering the hormone daily allows for consistent maintenance of therapeutic levels, which is crucial for stimulating bone formation and reducing the risk of fractures. The pharmacokinetics of Abaloparatide support this frequency, as it has a relatively short half-life and requires regular dosing to effectively promote bone density improvement.

Other frequencies such as weekly, monthly, or every other week are not appropriate for Abaloparatide due to the need for steady hormone levels to achieve optimal therapeutic outcomes. In the context of osteoporosis treatment, daily administration aligns with the goal of continuously stimulating osteoblastic activity while minimizing the risk of side effects associated with fluctuating hormone levels.